A sensitive gas chromatographic mass spectrometric assay for a novel dopamine agonist (+)-trans-3,4,4A,5,6,10B-hexahydro-4-propyl-2H-naphth(1,2-B)(1,4) oxazin-9-ol in human plasma.
(+)-trans-3,4,4A,5,6,10B-Hexahydro-4-propyl-2H-naphth(1,2-B)(1,4) oxazine-9-ol is a novel potent dopamine agonist. A sensitive and specific gas chromatographic/mass spectrometric assay procedure has been developed for the determination of the dopamine agonist at low picogram per millilitre levels in human plasma. The method comprises an extraction of the agonist from human plasma and subsequent derivatization of the phenolic functionality with pentafluoropropionic anhydride. The derivative is quantified by gas chromatographic and mass spectrometric detection using selected ion monitoring. The assay is linear over the concentration range 10-1000 pg ml-1.
D000978:Antiparkinson Agents / Q000097:blood; D015259:Dopamine Agents / Q000097:blood*; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods*; D006801:Humans; D066298:In Vitro Techniques; D010078:Oxazines / Q000097:blood*
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D010078:Oxazines; C042631:naxagolide